Tulathromycin A

• CAT Number: I002663
• CAS Number: 217500-96-4
• Molecular Formula: C41H79N3O12
• Molecular Weight: 806.1
• Purity: ≥95%
• Target: Antibiotic
• Solubility: DMSO: ≥ 45 mg/mL
• Storage: Store at -20°C
• IC50: 1 microg/ml (MIC90 for Pasteurella multocida) [2]
• InChIKey: GUARTUJKFNAVIK-QPTWMBCESA-N

Tulathromycin A is a macrolide antibiotic.IC50 Value: 1 microg/ml (MIC90 for Pasteurella multocida) [2]Target: Antibacterialin vitro: Two highly pathogenic strains of M. bovis (with minimum inhibitory concentration values for tulathromycin of 1 and >64 microg/ml) were inoculated into 145 calves. Four days after inoculation, calves with clinical BRD were treated subcutaneously with saline or tulathromycin (2.5 mg/kg). Compared with saline, BRD-related withdrawals, peak rectal temperatures, and lung lesion scores were significantly lower for tulathromycin-treated calves (P < .01). Tulathromycin was highly effective in the treatment of BRD due to M. bovis in calves regardless of the minimum inhibitory concentration of the challenge strain (1 or >64 microg/ml) [1]. The lowest concentrations inhibiting the growth of 90% of isolates (MIC90) for tulathromycin were 2 microg/ml for Mannheimia (Pasteurella) haemolytica, 1 microg/ml for Pasteurella multocida (bovine), and 2 microg/ml for Pasteurella multocida (porcine) and ranged from 0.5 to 4 microg/ml for Histophilus somni (Haemophilus somnus) and from 4 to 16 microg/ml for Actinobacillus pleuropneumoniae [2].in vivo: Each study randomly allocated 250 calves to receivetulathromycin at 2.5 mg/kg and 250 calves to receive either tilmicosin at 10 mg/kg (Colorado site) or florfenicol at 40 mg/kg (Idaho and Texas sites) on arrival at the feedlot. Calves were housed by treatment group in pens with 50 calves/pen [3]. The treatment groups were physiologic saline (n = 160) given SC at 0.02 ml/kg, tulathromycin (n = 320) given SC at 2.5 mg/kg, and tilmicosin (n = 320) given SC at 10 mg/kg [4].Tulathromycin is a triamilide antimicrobial that has been approved for use in the treatment and prevention of bovine respiratory disease and the treatment of swine respiratory disease.Toxicity: No adverse events related to tulathromycin were reported [4].Clinical trial:

Reference

[1]. Godinho KS, et al. Efficacy of tulathromycin in the treatment of bovine respiratory disease associated with induced Mycoplasma bovis infections in young dairy calves. Vet Ther. 2005 Summer;6(2):96-112.
[2]. Godinho KS, et al. Minimum inhibitory concentrations of tulathromycin against respiratory bacterial pathogens isolated from clinical cases in European cattle and swine and variability arising from changes in in vitro methodology. Vet Ther. 2005 Summer;6(2):113-21.
[3]. Rooney KA, et al. Efficacy of tulathromycin compared with tilmicosin and florfenicol for the control of respiratory disease in cattle at high risk of developing bovine respiratory disease. Vet Ther. 2005 Summer;6(2):154-66.
[4]. Kilgore WR, et al. Therapeutic efficacy of tulathromycin, a novel triamilide antimicrobial, against bovine respiratory disease in feeder calves. Vet Ther. 2005 Summer;6(2):143-53.